Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Identifying Potential Ageing-Modulating Drugs In Silico


Partridge,  L.
Department Partridge - Biological Mechanisms of Ageing, Max Planck Institute for Biology of Ageing, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Donertas, H. M., Fuentealba, M., Partridge, L., & Thornton, J. M. (2018). Identifying Potential Ageing-Modulating Drugs In Silico. Trends Endocrinol Metab, 30(2), 118-131. doi:10.1016/j.tem.2018.11.005.

Cite as: https://hdl.handle.net/21.11116/0000-000B-4303-6
Increasing human life expectancy has posed increasing challenges for healthcare systems. As people age, they become more susceptible to chronic diseases, with an increasing burden of multimorbidity, and the associated polypharmacy. Accumulating evidence from work with laboratory animals has shown that ageing is a malleable process that can be ameliorated by genetic and environmental interventions. Drugs that modulate the ageing process may delay or even prevent the incidence of multiple diseases of ageing. To identify novel, anti-ageing drugs, several studies have developed computational drug-repurposing strategies. We review published studies showing the potential of current drugs to modulate ageing. Future studies should integrate current knowledge with multi-omics, health records, and drug safety data to predict drugs that can improve health in late life.